

Dear Kate Moore,

In reviewing the ERG report, an error in the submission has come to light.

In the original submission, it is stated utilities were provided for  $\geq 1$  prior treatment (Table 6.11). We now realise the utilities provided were based on responses using all patients, not just previously treated patients.

Revised tables of utilities are provided below, for not only the  $\geq 1$  prior treatment, but also the  $\geq 2$  prior treatment and  $\geq 3$  prior treatment groups.

**Table 1:** Revised utility values for patients with  $\geq 1$  prior treatment. Utilities split by health state and treatment

Health State	Botox			Placebo		
	n	Mean	SE	n	Mean	SE
0 - 3	49	0.74	0.020	27	0.678	0.029
4 - 9	94	0.712	0.013	76	0.645	0.015
10 - 14	66	0.645	0.017	79	0.59	0.018
15 - 19	49	0.572	0.022	68	0.563	0.025
20 - 23	25	0.499	0.044	37	0.575	0.029
24 +	28	0.528	0.035	60	0.474	0.028

**Table 2:** Revised utility values for patients with  $\geq 2$  prior treatment. Utilities split by health state and treatment

Health State	Botox			Placebo		
	n	Mean	SE	n	Mean	SE
0 - 3	35	0.731	0.022	19	0.676	0.037
4 - 9	67	0.708	0.015	55	0.643	0.018
10 - 14	52	0.641	0.019	56	0.586	0.021
15 - 19	32	0.567	0.026	47	0.552	0.032
20 - 23	21	0.498	0.051	27	0.576	0.038
24 +	17	0.5	0.053	46	0.472	0.033

**Table 3:** Revised utility values for patients with  $\geq 3$  prior treatment. Utilities split by health state and treatment

Health State	Botox			Placebo		
	n	Mean	SE	n	Mean	SE
0 - 3	24	0.691	0.028	13	0.669	0.053
4 - 9	45	0.699	0.018	40	0.638	0.022
10 - 14	36	0.635	0.024	44	0.565	0.024
15 - 19	26	0.561	0.028	36	0.55	0.037
20 - 23	18	0.462	0.054	21	0.597	0.039
24 +	15	0.501	0.055	41	0.461	0.035

The impact on the ICER is small in each case, ranging from £5,347 in the  $\geq 1$  prior treatment group, to £6,434 in the  $\geq 3$  prior treatment group.

**Table 6.4:** Cost-effectiveness results using different sources of utility valuations

Treatment Arm	Totals		Discounted Totals		Incremental Costs	Incremental QALYs	Cost per QALY
	Costs	QALYs	Costs	QALYs			
Utilities from all patients (submission base case)							
Placebo	£1,879	1.24	£1,839	1.22			
Botox	£2,419	1.34	£2,388	1.31	£549	0.09	£5,828
Utilities from patients with $\geq 1$ prior treatment (intended base case)							
Placebo	£1,879	1.22	£1,839	1.19			
Botox	£2,419	1.32	£2,388	1.29	£549	0.10	£5,347
Utilities from patients with $\geq 2$ prior treatments							
Placebo	£1,879	1.21	£1,839	1.18			
Botox	£2,419	1.31	£2,388	1.28	£549	0.10	£5,495
Utilities from patients with $\geq 3$ prior treatments							
Placebo	£1,879	1.20	£1,839	1.17			
Botox	£2,419	1.28	£2,388	1.25	£549	0.09	£6,434
Utilities from patients with $\geq 3$ prior treatments, with TPMs from patients with $\geq 3$ prior treatments							
Placebo	£1,936	1.18	£1,895	1.16			
Botox	£2,471	1.27	£2,438	1.24	£543	0.08	£6,681

We would like to apologise for the mistake, and are happy to provide any extra analyses or scenarios requested by either NICE or the ERG.

Yours sincerely,

████████████████████  
 ████████████████████, Health Economics, Pricing, Reimbursement and Market Access  
 Allergan EAME

23 Dec 2011